The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
Neoadjuvant therapy with immunotherapy in pMMR/MSS rectal cancer shows high response rates and favorable surgical outcomes, with manageable safety profiles. Short-course chemoradiotherapy demonstrates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results